RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort

被引：1
|
作者：
Gill, Amitoj [1 ]
Jayswal, Rani [2 ]
Weiss, Heidi [2 ]
Rhodes, Jill [1 ]
Hegazi, Mohamed [1 ]
Herzig, Geoffrey [1 ]
Herzig, Roger [2 ]
Krem, Maxwell [2 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
[2] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
bortezomib; neuropathy; Tolerability;
D O I：
10.1016/j.clml.2019.09.349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-023
引用
收藏
页码：E210 / E210
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of a modified daratumumab/bortezomib/dexamethasone regimen using once weekly bortezomib in relapsed refractory multiple myeloma
    Abousaud, Marin
    Dressler, Emily
    Duda, Jessica
    Johnson, Emily
    Kennedy, LeAnne
    Rodriguez, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E150 - E151
  • [22] Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients
    Takezako, Naoki
    Tokuhira, Michihide
    Sekiguchi, Naohiro
    Kizaki, Masahiro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E142 - E143
  • [23] The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients
    Takezako, Naoki
    Tokuhira, Michihide
    Sekiguchi, Naohiro
    Kurihara, Yuya
    Ito, Kenichi
    Kurimoto, Miwa
    Suzuki, Kenshi
    Kizaki, Masahiro
    BLOOD, 2016, 128 (22)
  • [24] Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits
    Petrucci, Maria Teresa
    Finsinger, Paola
    Chisini, Marta
    Gentilini, Fabiana
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 939 - 946
  • [25] Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma
    Brioli, Annamaria
    Zannetti, Beatrice Anna
    Zamagni, Elena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Pezzi, Annalisa
    Rocchi, Serena
    Cavo, Michele
    HAEMATOLOGICA, 2014, 99 (11)
  • [26] Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma
    Takamatsu, Yasushi
    Imamura, Yutaka
    Nakazato, Tomonori
    Uike, Naokuni
    Miyashita, Kaname
    Saburi, Yoshio
    Harada, Naoki
    Ota, Shuichi
    Imamura, Rie
    Miyamoto, Toshihiro
    BLOOD, 2013, 122 (21)
  • [27] Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma
    Ong, Shin-Yeu
    Ng, Hong Yen
    Surendran, Shilpa
    Linn, Yeh Ching
    Chen, YunXin
    Goh, Yeow Tee
    Diong, Colin
    Gopalakrishnan, Sathish Kumar
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 754 - 756
  • [28] Retrospective analysis of weekly administration of bortezomib in multiple myeloma.
    Sayar, H
    Lee, FC
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [29] Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy
    Junya Kuroda
    Shinsuke Mizutani
    Yuji Shimura
    Saori Maegawa
    Hisao Nagoshi
    Yoshiaki Chinen
    Shotaro Tatekawa
    Taku Tsukamoto
    Yoshimi Mizuno
    Mio Yamamoto-Sugitani
    Tsutomu Kobayashi
    Yosuke Matsumoto
    Shigeo Horiike
    Masafumi Taniwaki
    Annals of Hematology, 2015, 94 : 687 - 689
  • [30] Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy
    Kuroda, Junya
    Mizutani, Shinsuke
    Shimura, Yuji
    Maegawa, Saori
    Nagoshi, Hisao
    Chinen, Yoshiaki
    Tatekawa, Shotaro
    Tsukamoto, Taku
    Mizuno, Yoshimi
    Yamamoto-Sugitani, Mio
    Kobayashi, Tsutomu
    Matsumoto, Yosuke
    Horiike, Shigeo
    Taniwaki, Masafumi
    ANNALS OF HEMATOLOGY, 2015, 94 (04) : 687 - 689
12345